Our findings are concordant with a recent study showing that agonist CD137 antibody induced the expression of PD-1 on CD8+ and CD4+ TILs from mice bearing B16 melanoma when they were immunized with a cell-based vaccine [42]. Here, TNFRSF9 is linked to melanoma.